[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345512-105":59,"doc-detail-345512-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trastuzumab-deruxtecan-in-her2-expressing-gynecologic-cancers-from-destiny-pantumor02-antitumor-activity-safety-and-exploratory-biomarker-analyses","Trastuzumab deruxtecan in - HER2-expressing gynecologic cancers from DESTINY-PanTumor02 - antitumor activity, safety, and exploratory biomarker analyses","","Objective: Investigate antitumor activity, safety, and exploratory subgroup analyses for trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecologic cancers. Methods: DESTINY-PanTumor02 is a 2-part, open-label, multicenter phase 2 study; pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing solid tumors received T-DXd 5.4 mg/kg. Primary endpoint was investigator-assessed confirmed objective response rate (ORR); secondary endpoints included safety, ORR by independent central review, progression-free survival, and overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trastuzumab-deruxtecan-in-her2-expressing-gynecologic-cancers-from-destiny-pantumor02-antitumor-activity-safety-and-exploratory-biomarker-analyses/345512/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trastuzumab-deruxtecan-in-her2-expressing-gynecologic-cancers-from-destiny-pantumor02-antitumor-activity-safety-and-exploratory-biomarker-analyses/345512.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the objective of the study?","Question",{"text":112,"@type":113},"The study evaluates antitumor activity and safety of trastuzumab deruxtecan (T-DXd), along with exploratory subgroup analyses in HER2-expressing gynecologic cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is DESTINY-PanTumor02 designed and who receives treatment?",{"text":117,"@type":113},"DESTINY-PanTumor02 is a 2-part, open-label, multicenter phase 2 study. Pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing solid tumors received T-DXd 5.4 mg/kg.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the primary and key secondary endpoints?",{"text":121,"@type":113},"The primary endpoint is investigator-assessed confirmed objective response rate (ORR). Secondary endpoints include safety, ORR by independent central review, progression-free survival, and overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345512,1790174787,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","J Gynecol Oncol. 2026 May;37(3):e65 [https://doi.org/10.3802/jgo.2026.37.e65](https://doi.org/10.3802/jgo.2026.37.e65)[ ](https://doi.org/10.3802/jgo.2026.37.e65)pISSN 2005-0380·eISSN 2005-0399  \nOriginal Article  \nReceived: Jan 19, 2026  \nRevised: Apr 2, 2026  \nAccepted: Apr 10, 2026  \nPublished online: May 6, 2026  \nCorrespondence to  \nJung-Yun Lee  \nDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.  \nEmail: [jungyunlee@yuhs.ac](jungyunlee@yuhs.ac)  \n*Jung-Yun Lee and Ana Oaknin contributed equally to this work as co-first authors.  \n†Current affiliation: Medical Oncology Department, Gynaecological Cancer Program, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain  \n© 2026. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nJung-Yun Lee   \n[https://orcid.org/0000-0001-7948-1350](https://orcid.org/0000-0001-7948-1350)  \nTrastuzumab deruxtecan in  \nHER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses  \nJung-Yun Lee ,1,* Ana Oaknin ,2,*,† Luis Manso ,3 Antonio González-Martín ,4 Iwona Ługowska ,5 Domenica Lorusso ,6,7 Susana Banerjee ,8,9 John B. Liao ,10 Chien-Hsing Lu ,11 Naiyarat Prasongsook ,12 Bohuslav Melichar ,13  \nChiedozie Anoka ,14 Lindsey Jung ,15 Flavia Michelini ,16 Soham Puvvada ,17 Funda Meric-Bernstam ,18 Vicky Makker  19,20  \n1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea  \n2Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain  \n3Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain  \n4Medical Oncology Department and Programme in Solid Tumours CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, Spain  \n5Center for Excellence in Precision Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland  \n6Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy  \n7Humanitas San Pio X, Milan, Italy  \n8Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK  \n9Institute of Cancer Research, London, UK  \n10Division of Gynecologic Oncology, University of Washington, Seattle, WA, USA  \n11Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan 12Division of Medical Oncology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand 13Department of Oncology, Palacky University Medical School and University Hospital, Olomouc, Czech Republic  \n14Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA  \n15Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA  \n16Translational Medicine, Oncology R&D, AstraZeneca, Barcelona, Spain  \n17Clinical Development, Late Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 18Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA  \n19Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA 20Department of Medicine, Weill Cornell Medical College, New York, NY, USA  \nABSTRACT  \nObjective: To investigate antitumor activity, safety, and exploratory subgroup analyses fortrastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2) -expressing","cbCaihodDZ2SKo23","https://ap.wps.com/l/cbCaihodDZ2SKo23","pdf",2571874,"English","# Abstract\n## Objective\n## Methods\n## Endpoints","[{\"question\":\"What is the objective of the study?\",\"answer\":\"The study evaluates antitumor activity and safety of trastuzumab deruxtecan (T-DXd), along with exploratory subgroup analyses in HER2-expressing gynecologic cancers.\"},{\"question\":\"How is DESTINY-PanTumor02 designed and who receives treatment?\",\"answer\":\"DESTINY-PanTumor02 is a 2-part, open-label, multicenter phase 2 study. Pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing solid tumors received T-DXd 5.4 mg/kg.\"},{\"question\":\"What are the primary and key secondary endpoints?\",\"answer\":\"The primary endpoint is investigator-assessed confirmed objective response rate (ORR). Secondary endpoints include safety, ORR by independent central review, progression-free survival, and overall survival.\"}]","Trastuzumab deruxtecan in - HER2-expressing gynecologic cancers from DESTINY-PanTumor02 - antitumor activity, safety, and exploratory biomarker analyses | PDF",1790057930]